studies

mML - (neo)adjuvant (NA), ipilimumab alone vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 238, 2017 0.87 [0.66; 1.14] EORTC 18071, 2015 0.72 [0.58; 0.89] 0.77[0.65; 0.93]CheckMate 238, 2017, EORTC 18071, 2015214%1,857lownot evaluable deaths (OS) (extension)detailed resultsEORTC 18071, 2015 0.73 [0.64; 0.83] 0.73[0.64; 0.83]EORTC 18071, 201510%951NAnot evaluable MFSdetailed resultsCheckMate 238, 2017 0.73 [0.56; 0.96] EORTC 18071, 2015 0.76 [0.63; 0.91] 0.75[0.65; 0.87]CheckMate 238, 2017, EORTC 18071, 201520%1,686lownot evaluable MFS (extension)detailed resultsEORTC 18071, 2015 0.76 [0.64; 0.90] 0.76[0.64; 0.90]EORTC 18071, 201510%951NAnot evaluable RFS (extension)detailed resultsCheckMate 238, 2017 0.71 [0.59; 0.85] EORTC 18071, 2015 0.75 [0.63; 0.89] 0.73[0.65; 0.83]CheckMate 238, 2017, EORTC 18071, 201520%1,857lownot evaluable RFS/DFSdetailed resultsCheckMate 238, 2017 0.65 [0.51; 0.83] EORTC 18071, 2015 0.75 [0.63; 0.89] 0.72[0.62; 0.82]CheckMate 238, 2017, EORTC 18071, 201520%1,857lownot evaluable AE (any grade)detailed resultsCheckMate 238, 2017 0.49 [0.20; 1.23] EORTC 18071, 2015 7.53 [3.17; 17.90] 1.93[0.13; 28.07]CheckMate 238, 2017, EORTC 18071, 2015294%1,850lownot evaluable AE (grade 3-4)detailed resultsCheckMate 238, 2017 0.28 [0.21; 0.37] EORTC 18071, 2015 0.11 [0.08; 0.17] 0.18[0.08; 0.43]CheckMate 238, 2017, EORTC 18071, 2015293%1,850lownot evaluable AE leading to treatment discontinuation (any grade)detailed resultsCheckMate 238, 2017 0.15 [0.10; 0.21] 0.15[0.10; 0.21]CheckMate 238, 201710%905NAnot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsCheckMate 238, 2017 0.11 [0.07; 0.18] 0.11[0.07; 0.18]CheckMate 238, 201710%905NAnot evaluable TRAE (any grade)detailed resultsCheckMate 238, 2017 0.25 [0.15; 0.43] EORTC 18071, 2015 14.40 [10.07; 20.60] 1.91[0.04; 100.98]CheckMate 238, 2017, EORTC 18071, 2015299%1,850lownot evaluable TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.20 [0.14; 0.27] EORTC 18071, 2015 25.27 [14.14; 45.18] 2.22[0.02; 257.63]CheckMate 238, 2017, EORTC 18071, 20152100%1,850lownot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 238, 2017 0.25 [0.01; 5.55] EORTC 18071, 2015 10.16 [0.55; 186.52] 1.66[0.04; 62.62]CheckMate 238, 2017, EORTC 18071, 2015266%1,850lownot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 238, 2017 0.12 [0.08; 0.17] EORTC 18071, 2015 21.35 [13.41; 33.97] 1.58[0.01; 259.15]CheckMate 238, 2017, EORTC 18071, 20152100%1,850lownot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCheckMate 238, 2017 0.09 [0.05; 0.15] 0.09[0.05; 0.15]CheckMate 238, 201710%905NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.50 [0.02; 14.96] 0.50[0.02; 14.96]CheckMate 238, 201710%905NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.50 [0.09; 2.74] 0.50[0.09; 2.74]CheckMate 238, 201710%905NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.50 [0.05; 5.53] 0.50[0.05; 5.53]CheckMate 238, 201710%905NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.25 [0.03; 2.24] 0.25[0.03; 2.24]CheckMate 238, 201710%905NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsEORTC 18071, 2015 39.14 [5.34; 286.74] 39.14[5.34; 286.74]EORTC 18071, 201510%945NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 2.01 [0.07; 59.97] 2.01[0.07; 59.97]CheckMate 238, 201710%905NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.15 [0.07; 0.34] EORTC 18071, 2015 25.54 [6.16; 105.87] 1.89[0.01; 290.44]CheckMate 238, 2017, EORTC 18071, 2015297%1,850lownot evaluable Endocrine disorders TRAE (grade 3-4) detailed resultsEORTC 18071, 2015 42.70 [5.84; 312.15] 42.70[5.84; 312.15]EORTC 18071, 201510%945NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.50 [0.09; 2.74] 0.50[0.09; 2.74]CheckMate 238, 201710%905NAnot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsCheckMate 238, 2017 0.10 [0.05; 0.20] EORTC 18071, 2015 22.61 [8.20; 62.34] 1.49[0.01; 299.98]CheckMate 238, 2017, EORTC 18071, 2015299%1,850lownot evaluable Headache TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.14 [0.02; 1.15] 0.14[0.02; 1.15]CheckMate 238, 201710%905NAnot evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed resultsCheckMate 238, 2017 0.15 [0.07; 0.32] EORTC 18071, 2015 57.44 [7.90; 417.44] 2.71[0.01; 929.94]CheckMate 238, 2017, EORTC 18071, 2015297%1,850lownot evaluable Hypersensitivity TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 2.01 [0.07; 59.97] 2.01[0.07; 59.97]CheckMate 238, 201710%905NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 1.00 [0.06; 16.07] 1.00[0.06; 16.07]CheckMate 238, 201710%905NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.18 [0.04; 0.81] EORTC 18071, 2015 44.19 [2.67; 732.31] 2.46[0.01; 542.19]CheckMate 238, 2017, EORTC 18071, 2015291%1,850lownot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.50 [0.05; 5.53] 0.50[0.05; 5.53]CheckMate 238, 201710%905NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.10 [0.02; 0.44] 0.10[0.02; 0.44]CheckMate 238, 201710%905NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.18 [0.07; 0.48] 0.18[0.07; 0.48]CheckMate 238, 201710%905NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.05 [0.00; 0.95] 0.05[0.00; 0.95]CheckMate 238, 201710%905NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 2.01 [0.07; 59.97] 2.01[0.07; 59.97]CheckMate 238, 201710%905NAnot evaluable Nervous system disorders TRAE (grade 3-4)detailed resultsEORTC 18071, 2015 18.45 [1.07; 319.15] 18.45[1.07; 319.15]EORTC 18071, 201510%945NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.10 [0.01; 1.82] 0.10[0.01; 1.82]CheckMate 238, 201710%905NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.25 [0.01; 5.55] 0.25[0.01; 5.55]CheckMate 238, 201710%905NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 0.35 [0.13; 0.98] EORTC 18071, 2015 10.16 [0.55; 186.52] 1.42[0.05; 36.59]CheckMate 238, 2017, EORTC 18071, 2015278%1,850lownot evaluable Renal and urinary disorders TRAE (grade 3-4) detailed resultsCheckMate 238, 2017 1.00 [0.02; 50.62] 1.00[0.02; 50.62]CheckMate 238, 201710%905NAnot evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed resultsCheckMate 238, 2017 0.12 [0.01; 2.36] 0.12[0.01; 2.36]CheckMate 238, 201710%905NAnot evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed resultsCheckMate 238, 2017 0.18 [0.07; 0.46] EORTC 18071, 2015 42.00 [2.53; 697.02] 2.31[0.01; 487.21]CheckMate 238, 2017, EORTC 18071, 2015292%1,850lownot evaluable Abdominal pain AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.04 [0.01; 0.17] 0.04[0.01; 0.17]EORTC 18071, 201510%945NAnot evaluable Colitis AE (grade 3-4)detailed resultsEORTC 18071, 2015 6.26 [2.61; 15.03] 6.26[2.61; 15.03]EORTC 18071, 201510%945NAnot evaluable Cough AE (grade 3-4)detailed resultsOut of scaleEORTC 18071, 2015 0.01 [0.00; 0.15] 0.01[0.00; 0.15]EORTC 18071, 201510%945NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.06 [0.01; 0.46] 0.06[0.01; 0.46]EORTC 18071, 201510%945NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.26 [0.18; 0.37] 0.26[0.18; 0.37]EORTC 18071, 201510%945NAnot evaluable Fatigue AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.05 [0.03; 0.10] 0.05[0.03; 0.10]EORTC 18071, 201510%945NAnot evaluable Headache AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.04 [0.01; 0.11] 0.04[0.01; 0.11]EORTC 18071, 201510%945NAnot evaluable Hypophysitis AE (grade 3-4)detailed resultsEORTC 18071, 2015 11.01 [2.57; 47.24] 11.01[2.57; 47.24]EORTC 18071, 201510%945NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.14 [0.02; 1.16] 0.14[0.02; 1.16]EORTC 18071, 201510%945NAnot evaluable Increase AST AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.80 [0.45; 1.45] 0.80[0.45; 1.45]EORTC 18071, 201510%945NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.97 [0.55; 1.70] 0.97[0.55; 1.70]EORTC 18071, 201510%945NAnot evaluable Nausea AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.01 [0.00; 0.07] 0.01[0.00; 0.07]EORTC 18071, 201510%945NAnot evaluable Pruritus AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.14 [0.07; 0.26] 0.14[0.07; 0.26]EORTC 18071, 201510%945NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.21 [0.08; 0.56] 0.21[0.08; 0.56]EORTC 18071, 201510%945NAnot evaluable Rash AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.06 [0.03; 0.15] 0.06[0.03; 0.15]EORTC 18071, 201510%945NAnot evaluable Vomiting AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.07 [0.02; 0.29] 0.07[0.02; 0.29]EORTC 18071, 201510%945NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsEORTC 18071, 2015 0.02 [0.00; 0.16] 0.02[0.00; 0.16]EORTC 18071, 201510%945NAnot evaluable0.0100.01.0relative treatment effectwww.metaEvidence.org2024-06-15 02:28 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 284,70,235 - treatments: 329,558

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons